Comparative Retrospective Analysis of pNETs Treatment with Everolimus (E) and Sunitinib (S).

#1702

Introduction: Two targeted compounds are validated for treatment of pNETs – E and S.

Aim(s): We performed retrospective analysis of pts with pNETs treated with E or S. Previously these pts have not been treated with either of these drugs.

Materials and methods: 20 pts with progressive pNETs (G1,G2) were treated with E and 16 pts with S 37,5 mg or 50mg dose regimen. All pts were on treatment with long acting octreotide. The mean age was 47 years in E group and 53 in S group. Most pts had liver metastases – 17/20 (85%) in E group and 15/16 (93%) in S group, regional l/nodes – in 6/20 (30%) and 6/16 (38%) and not regional l/nodes in – 4/20 (20%) and 4/16 (25%) pts respectively. Only 4 pts in each group were heavily pretreated with 3 or more lines of chemotherapy. G1 tumor was in 3 pts (E group) and no one in S group. Cytoreductive surgery was performed in 8 (40%) pts (E) and 9 (56%) pts (S).

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Kouzminov A, Odintsova A, Polozkova S, Orel N, Markovich A,

Keywords: pNETs, sunitinib, everolimus,

To read the full abstract, please log into your ENETS Member account.